# Fresenius Kabi clinical trials: 51 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Fresenius Kabi as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Fresenius Kabi: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/fresenius-kabi

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 18, 2026 | NCT07479251 | Glycaemic Index Measurement of an Oral Nutritional Supplement With Biomarker Assessment and Lifestyle Monitoring in Healthy Participants | Fresenius Kabi | Not applicable | Not yet recruiting | Healthy Participants | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479251) |
| February 23, 2024 | NCT06274788 | Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | Fresenius Kabi | Observational | Recruiting | Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06274788) |
| September 22, 2023 | NCT06049680 | Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients | Fresenius Kabi | Phase 4 | Recruiting | Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06049680) |
| February 25, 2022 | NCT05257031 | Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care | Fresenius Kabi | Phase 3 | Completed | Nutrition Therapy, Critical Illness | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05257031) |
| January 13, 2022 | NCT05190484 | bIosimilar of aDalimumab, an European evAluation | Fresenius Kabi | Observational | Unknown | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn Disease, Ulcerative Colitis | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05190484) |
| September 21, 2021 | NCT05051943 | A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response | Fresenius Kabi | Observational | Completed | Crohn Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis | 754 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05051943) |
| March 19, 2021 | NCT04807478 | Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC) | Fresenius Kabi | Observational | Withdrawn | Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency, Neurocognitive Deficit, Malnutrition... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04807478) |
| October 29, 2019 | NCT04143503 | Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients | Fresenius Kabi | Observational | Completed | Critical Illness | 1,208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143503) |
| June 20, 2019 | NCT03992716 | Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness | Fresenius Kabi | Phase 4 | Terminated | Critical Illness | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992716) |
| January 3, 2019 | NCT03792100 | Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition | Fresenius Kabi | Phase 3 | Completed | Parenteral Nutrition, Surgery | 273 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03792100) |
| January 3, 2019 | NCT03792087 | Efficacy and Safety of SmofKabiven Peripheral Versus Compounded Emulsion | Fresenius Kabi | Phase 3 | Completed | Parenteral Feeding, Surgery | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03792087) |
| September 12, 2018 | NCT03666546 | Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2 | Fresenius Kabi | Phase 4 | Completed | Diabetes Mellitus, Type 2 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03666546) |
| August 8, 2018 | NCT03619564 | Chronic Kidney Disease Observational Database - Taiwan | Fresenius Kabi | Observational | Completed | Chronic Kidney Insufficiency | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03619564) |
| July 31, 2018 | NCT03606603 | Nutrition Insights Day Asia | Fresenius Kabi | Observational | Completed | Nutritional Status, Malnutrition, Caloric Deficit, Protein Deficiency | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03606603) |
| June 20, 2018 | NCT03563222 | Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age | Fresenius Kabi | Phase 4 | Terminated | Malnutrition, Child | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03563222) |
| March 29, 2018 | NCT03481894 | Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age | Fresenius Kabi | Phase 4 | Withdrawn | Malnutrition | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03481894) |
| February 7, 2018 | NCT03425435 | Quality of Care of Oncological Patients With HPN | Fresenius Kabi | Observational | Terminated | Tumors and Home Parenteral Nutrition | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03425435) |
| November 28, 2017 | NCT03355079 | Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy | Fresenius Kabi | Phase 4 | Terminated | Cancer-related Malnutrition | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03355079) |
| November 9, 2017 | NCT03338218 | Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients | Fresenius Kabi | Phase 4 | Completed | Hypovolemia Due to Acute Blood Loss | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03338218) |
| September 15, 2017 | NCT03284398 | Three-Chamber Bags Retrospective Study in Spain | Fresenius Kabi | Observational | Completed | Parenteral Nutrition, Blood Stream Infection | 3,723 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03284398) |
| September 11, 2017 | NCT03278548 | Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal... | Fresenius Kabi | Phase 4 | Completed | Hypovolaemia Due to Acute Blood Loss | 2,289 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03278548) |
| March 10, 2017 | NCT03077048 | Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients | Fresenius Kabi | Phase 1/2 | Completed | Renal Insufficiency, Chronic | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03077048) |
| November 18, 2016 | NCT02968498 | Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers | Fresenius Kabi | Not applicable | Completed | Blood Glucose | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02968498) |
| October 19, 2016 | NCT02938247 | Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake | Fresenius Kabi | Not applicable | Completed | Malnutrition | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02938247) |
| October 19, 2016 | NCT02938234 | Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake | Fresenius Kabi | Not applicable | Completed | Malnutrition | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02938234) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 7 |
| Phase 4 | 16 |
| Not applicable | 13 |
| Observational | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Terminated | 9 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Malnutrition | 10 |
| Hyperphagia | 10 |
| Renal Insufficiency, Chronic | 5 |
| Critical Illness | 3 |
| Neoplasms | 3 |
| Child Nutrition Disorders | 2 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Crohn Disease | 2 |
| Colitis, Ulcerative | 2 |
| Spondylitis, Ankylosing | 2 |
| Arthritis, Rheumatoid | 2 |
| Arthritis, Psoriatic | 2 |
| Cachexia | 2 |
| Postoperative Complications | 1 |
| Subarachnoid Hemorrhage | 1 |
| Insulin Resistance | 1 |
| Intraoperative Complications | 1 |
| Protein Deficiency | 1 |
| Psoriasis | 1 |
| Diabetic Nephropathies | 1 |
| Rectal Neoplasms | 1 |
| Sepsis | 1 |
| Hypotension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Product design firms in the United States](https://specstream.ai/data/businesses/product-design-firms/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Laboratory equipment suppliers in the United States](https://specstream.ai/data/businesses/laboratory-equipment-suppliers/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
